Gregory Everson MD
Hepatology & Liver Transplantation
CEO CMO HepQuant LLC
Join to View Full Profile
5251 DTC ParkwaySuite 300Greenwood Village, CO 80111
Phone+1 303-923-2147
Dr. Everson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of ColoradoFellowship, Gastroenterology, 1979 - 1981
Creighton University School of Medicine (Omaha)Residency, Internal Medicine, 1976 - 1979
Weill Cornell MedicineClass of 1976
Certifications & Licensure
CO State Medical License 1979 - 2027
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Gastroenterology
- American Board of Internal Medicine Transplant Hepatology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012, 2014-2017
- Fellow of the American Society of Transplantation AST, 2010
Clinical Trials
- Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment Start of enrollment: 2000 Jun 01
- Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C After Liver Transplantation Start of enrollment: 2005 Sep 01
- HCV-TARGET- Hepatitis C Therapeutic Registry and Research Network Start of enrollment: 2011 Nov 01
Publications & Presentations
PubMed
- Letter: Enhancing the Diagnostic Performance of the Oral Cholate Challenge Test: Implications for Avoidance of Potentially Unnecessary Endoscopy.Tarek Hassanein, Andrew P Keaveny, Parvez Mantry, Mitchell Shiffman, Michael Leise
Alimentary Pharmacology & Therapeutics. 2025-06-01 - 2 citationsRencofilstat Treatment Improves Liver Function in MASH With Advanced Fibrosis as Quantified by HepQuant DuO.Stephen A Harrison, Patrick Mayo, Todd Hobbs, Caroline Zhao, Carlos Canizares
Liver International. 2025-03-01 - 5 citationsCholate Shunt, Oral Cholate Challenge and Endoscopic Lesions of Portal Hypertension: The SHUNT-V Study.Mitchell Shiffman, K Rajender Reddy, Michael D Leise, Kamran Qureshi, Alastair D Smith
Alimentary Pharmacology & Therapeutics. 2025-01-01
Press Mentions
HepQuant Presents Exciting Abstracts at the Liver Meeting 2025 Demonstrating HepQuant DuO® Utility to Uncover Functional and Physiological HeterogeneityNovember 6th, 2025- HepQuant Announces Exciting New Data Utilizing HepQuant DuO® Testing: Early Assessment of Resmetirom Treatment Benefit in Patients with Compensated MASH CirrhosisOctober 14th, 2025
- HepQuant Presents a New Application for the HepQuant DuO™ Test: Improved Study Design and Treatment Monitoring in Clinical TrialsOctober 2nd, 2025
Professional Memberships
- Fellow
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
